CAS 668270-11-9

1H-Purine-2,6-dione,8-[(3S)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-

Description:

1H-Purine-2,6-dione, 8-[(3S)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- is a complex organic compound characterized by its purine core structure, which is a bicyclic compound consisting of fused imidazole and pyrimidine rings. This substance features multiple functional groups, including an amino group, a piperidine ring, and a butynyl side chain, contributing to its potential biological activity. The presence of the quinazoline moiety suggests possible interactions with biological targets, making it of interest in medicinal chemistry, particularly in the development of pharmaceuticals. The compound's stereochemistry, indicated by the (3S) designation, implies specific spatial arrangements that can influence its biological interactions and efficacy. Additionally, its molecular structure suggests potential solubility and stability characteristics that are important for drug formulation. Overall, this compound exemplifies the complexity and diversity of synthetic organic molecules used in therapeutic applications.

Formula: C₂₅H₂₈N₈O₂

(S)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione (Linagliptin Impurity)

CAS: 668270-11-9

Purity: 97%

Color and Shape: Solid

Molecular weight: 472.553

Ref: 10-F988633

Linagliptin iMpurity G

CAS: 668270-11-9

Formula: C₂₅H₂₈N₈O₂

Purity: 95%

Color and Shape: Solid

Molecular weight: 472.5422

Ref: IN-DA00FGX3

(S)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione

CAS: 668270-11-9

(S)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione

Purity: 95%

Molecular weight: 472.55g/mol

Ref: 54-OR1070957

(S)-Linagliptin

CAS: 668270-11-9

Formula: C₂₅H₂₈N₈O₂

Color and Shape: Pale Yellow Solid

Molecular weight: 472.55

Ref: 4Z-L-4423

(S)-Linagliptin

CAS: 668270-11-9

Applications (S)-Linagliptin is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
References Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011);

Formula: C₂₅H₂₈N₈O₂

Color and Shape: Neat

Molecular weight: 472.54

Ref: TR-L465895

Linagliptin EP Impurity A

CAS: 668270-11-9

Formula: C₂₅H₂₈N₈O₂

Molecular weight: 472.54

Ref: ST-EA-CP-L1012

Linagliptin Enantiomer

CAS: 668270-11-9

Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoi

Formula: C₂₅H₂₈N₈O₂

Molecular weight: 472.23352

Ref: 45-1A04840

Linagliptin impurity G

CAS: 668270-11-9

Linagliptin impurity G is an impurity in the drug product Linagliptin. It is a natural substance and its CAS number is 668270-11-9. Impurity G can be synthesized from L-phenylalanine and cyclohexane carboxaldehyde in a two step process. The first step involves the reaction of L-phenylalanine with cyclohexane carboxaldehyde to yield methylcyclohexanecarboxylate, which then undergoes hydrolysis to give phenylcyclohexanol. In the second step, phenylcyclohexanol reacts with hydrochloric acid to produce phenylcyclohexanone, which is then oxidized with hydrogen peroxide to yield impurity G. Impurity G can also be found in the pharmacopoeia as a high purity HPLC standard for linagliptin.

Formula: C₂₅H₂₈N₈O₂

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 472.54 g/mol

Ref: 3D-FA146003